Entering text into the input field will update the search result below

Krystal Biotech nabs U.S. patent covering HSV vectors

Jan. 16, 2018 10:46 AM ETKrystal Biotech, Inc. (KRYS) StockBy: Douglas W. House, SA News Editor1 Comment
  • The USPTO issues U.S. Patent No. 9,877,990 to Krystal Biotech (NASDAQ:KRYS +0.4%) covering compositions comprising herpes simplex viral (HSV) vectors and methods of using the compositions to treat or prevent skin wounds and disorders.
  • The company's lead candidate is preclinical-stage KB103, a gene therapy to treat dystrophic epidermolysis bullosa, an inherited disorder characterized by skin blistering due to the lack of collagen. It is a replication-defective, non-integrating HSV-1 viral vector developed under the company's STAR-D platform that delivers genes that code for collagen directly to skin cells.

Recommended For You

About KRYS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
KRYS--
Krystal Biotech, Inc.